IMCIVREE

This brand name is authorized in Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Spain.

Active ingredients

The drug IMCIVREE contains one active pharmaceutical ingredient (API):

1	Setmelanotide UNII N7T15V1FUY - SETMELANOTIDE
	Setmelanotide is a selective MC4 receptor agonist. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. In genetic forms of obesity associated with insufficient activation of the MC4 receptor, setmelanotide is believed to re-establish MC4 receptor pathway activity to reduce hunger and promote weight loss through decreased caloric intake and increased energy expenditure.
	Read more about Setmelanotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
IMCIVREE Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A08AA12		A Alimentary tract and metabolism → A08 Antiobesity preparations, excl. diet products → A08A Antiobesity preparations, excl. diet products → A08AA Centrally acting antiobesity products
Discover more medicines within A08AA12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1857539
ES	Centro de información online de medicamentos de la AEMPS	1211564001
FR	Base de données publique des médicaments	69966525
IL	מִשְׂרַד הַבְּרִיאוּת	9018
IT	Agenzia del Farmaco	049605013, 049605025
LT	Valstybinė vaistų kontrolės tarnyba	1092974
PL	Rejestru Produktów Leczniczych	100464076